Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.
Por:
González-Cao M, Arance A, Piulats JM, Marquez-Rodas I, Manzano JL, Berrocal A, Crespo G, Rodriguez D, Perez-Ruiz E, Berciano M, Soria A, Castano AG, Espinosa E, Montagut C, Alonso L, Puertolas T, Aguado C, Royo MA, Blanco R, Rodríguez JF, Muñoz E, Mut P, Barron F, Martin-Algarra S and Spanish Melanoma Group
Publicada:
1 jun 2017
Resumen:
The programmed death (PD-1) inhibitor pembrolizumab has been recently approved for the treatment of advanced melanoma. We evaluated the clinical activity of pembrolizumab in melanoma patients treated under the Spanish Expanded Access Program.
Filiaciones:
González-Cao M:
Translational Cancer Research Unit, Dr. Rosell Oncology Institute, Quiron Dexeus University Hospital, 08028, Barcelona, Spain.
Arance A:
Hospital Clinic i Provincial, Barcelona, Spain
Piulats JM:
Catalan Institute of Oncology, Barcelona, Spain
Marquez-Rodas I:
Gregorio Marañón Institute of Health Research, Madrid, Spain
Manzano JL:
Germans Trias I Pujol University Hospital, Barcelona, Spain
Berrocal A:
General University Hospital, Valencia, Spain
Crespo G:
Burgos University Hospital, Burgos, Spain
Rodriguez D:
Insular University Hospital of Gran Canaria, Canary Islands, Spain
Perez-Ruiz E:
Costa del Sol Hospital, Marbella, Malaga, Spain
Berciano M:
Regional University Hospital of Malaga, Malaga, Spain
Soria A:
Ramony Cajal Hospital, Madrid, Spain
Castano AG:
Marqués de Valdecilla University Hospital, Santander, Spain
Espinosa E:
La Paz University Hospital, Madrid, Spain
Montagut C:
Del Mar University Hospital, Barcelona, Spain
Alonso L:
Virgen de la Victoria Hospital, Malaga, Spain
Puertolas T:
Miguel Servet University Hospital, Zaragoza, Spain
Aguado C:
San Carlos Hospital, Madrid, Spain
:
Dr. Peset Hospital, Valencia, Spain
Blanco R:
Consorci Sanitari de Terrassa, Barcelona, Spain
Rodríguez JF:
Clara Campal Hospital, Madrid, Spain
Muñoz E:
Valld'Hebron University Hospital, Barcelona, Spain
Mut P:
Son Llatzer University Hospital, Mallorca, Spain
Barron F:
National Cancer Institute, Mexico City, Mexico
Martin-Algarra S:
Navarra University Clinic, Pamplona, Spain
|